Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods Of Healthcare Delivery System01:26

Methods Of Healthcare Delivery System

3.9K
At the different levels of the healthcare system, we see varying methods of healthcare used. These methods include managed care systems, case management, and primary healthcare.
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
3.9K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

622
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
622
Relative Risk01:12

Relative Risk

2.4K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.4K
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

578
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
578
Actuarial Approach01:20

Actuarial Approach

382
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
382
Hazard Ratio01:12

Hazard Ratio

741
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
741

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishing multiple cost-effectiveness thresholds in Oman: a stakeholder-driven approach.

Health economics review·2026
Same author

Unlocking the benefits of allopurinol: the role of timely initiation and adherence in cardiovascular and renal outcomes in hyperuricemia.

European journal of internal medicine·2026
Same author

Transferability of Patient Selection Model for Proton Radiation Therapy to Lower-Income European Countries.

Value in health regional issues·2026
Same author

Policy barriers to drug repurposing in Europe: different stakeholder perspectives identified during survey-based shortlisting of key challenges.

Health policy OPEN·2026
Same author

Applicability of academic real-world data research in the case studies of the HTx project to practical health technology assessment work.

Frontiers in pharmacology·2026
Same author

Policy approach to optimize multiple myeloma treatment sequencing practices.

Expert review of hematology·2026

Related Experiment Video

Updated: Apr 23, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: November 1, 2010

17.7K

[Risk sharing methods in middle income countries].

András Inotai1, Zoltán Kaló

  • 1Syreon Kutató Intézet, Budapest, Thököly út 119. - 1146.

Acta Pharmaceutica Hungarica
|May 11, 2012
PubMed
Summary

Innovative medicine pricing is challenging for middle-income countries. Confidential pricing and outcome-based risk-sharing agreements can improve drug affordability and access by adjusting prices to local purchasing power.

Area of Science:

  • Health Economics
  • Pharmaceutical Policy

Background:

  • Innovative medicine pricing strategies are often benchmarked against major pharmaceutical markets, leading to high ex-factory prices.
  • International price referencing and parallel trade have narrowed the pricing corridor for new drugs, limiting negotiation power for middle-income countries.
  • Reimbursement at Western European prices may not be justifiable for Central-Eastern European countries due to economic disparities.

Purpose of the Study:

  • To review and assess financial and outcome-based risk-sharing methods for innovative medicines.
  • To explore how these schemes can address pricing challenges in middle-income countries.
  • To evaluate the impact of risk-sharing on transparency and differential pricing.

Main Methods:

  • Review of published literature on financial and outcome-based risk-sharing agreements.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K

Related Experiment Videos

Last Updated: Apr 23, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: November 1, 2010

17.7K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K
  • Analysis of confidential pricing mechanisms like discounts, claw-backs, and rebates.
  • Assessment of the implications of risk-sharing schemes on pharmaceutical pricing and reimbursement.

    • Main Results:

    • Confidential pricing agreements can enable differential pricing tailored to local purchasing power without affecting published ex-factory prices.
    • Financial risk-sharing agreements shift budget consequences to manufacturers but can paradoxically reduce spending through negative health outcomes.
    • Outcome-based risk-sharing agreements are emerging to improve healthcare quality and reduce medical uncertainty in coverage decisions.

    Conclusions:

    • Outcome-based risk-sharing schemes represent a significant advancement for drug reimbursement in middle-income countries.
    • These schemes can enhance the coverage of valuable innovative healthcare technologies by mitigating uncertainty.
    • However, risk-sharing agreements may reduce pricing transparency, necessitating careful implementation to ensure fair access and pricing.